JP2019512543A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019512543A5 JP2019512543A5 JP2018568165A JP2018568165A JP2019512543A5 JP 2019512543 A5 JP2019512543 A5 JP 2019512543A5 JP 2018568165 A JP2018568165 A JP 2018568165A JP 2018568165 A JP2018568165 A JP 2018568165A JP 2019512543 A5 JP2019512543 A5 JP 2019512543A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- inhibitor molecule
- nucleic acid
- catenin
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021193759A JP7321236B2 (ja) | 2016-03-16 | 2021-11-30 | β－カテニン関連疾患又は障害の治療のための組成物及び方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662309449P | 2016-03-16 | 2016-03-16 | |
| US62/309,449 | 2016-03-16 | ||
| US201662318529P | 2016-04-05 | 2016-04-05 | |
| US62/318,529 | 2016-04-05 | ||
| US201662365164P | 2016-07-21 | 2016-07-21 | |
| US62/365,164 | 2016-07-21 | ||
| PCT/US2017/022510 WO2017160983A1 (en) | 2016-03-16 | 2017-03-15 | Compositions and methods for the treatment of a beta-catenin-associated disease or disorder |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021193759A Division JP7321236B2 (ja) | 2016-03-16 | 2021-11-30 | β－カテニン関連疾患又は障害の治療のための組成物及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019512543A JP2019512543A (ja) | 2019-05-16 |
| JP2019512543A5 true JP2019512543A5 (enExample) | 2019-09-12 |
| JP6987084B2 JP6987084B2 (ja) | 2021-12-22 |
Family
ID=59850959
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018568165A Expired - Fee Related JP6987084B2 (ja) | 2016-03-16 | 2017-03-15 | β−カテニン関連疾患又は障害の治療のための組成物及び方法 |
| JP2021193759A Active JP7321236B2 (ja) | 2016-03-16 | 2021-11-30 | β－カテニン関連疾患又は障害の治療のための組成物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021193759A Active JP7321236B2 (ja) | 2016-03-16 | 2021-11-30 | β－カテニン関連疾患又は障害の治療のための組成物及び方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US10821112B2 (enExample) |
| EP (1) | EP3429598A4 (enExample) |
| JP (2) | JP6987084B2 (enExample) |
| AU (2) | AU2017232496B2 (enExample) |
| CA (1) | CA3017963A1 (enExample) |
| WO (1) | WO2017160983A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017232496B2 (en) * | 2016-03-16 | 2022-11-24 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for the treatment of a beta-catenin-associated disease or disorder |
| JP2021500026A (ja) * | 2017-10-18 | 2021-01-07 | ディセルナ ファーマシューティカルズ インコーポレイテッド | βカテニン核酸阻害剤分子 |
| US11813280B2 (en) | 2018-01-05 | 2023-11-14 | Dicerna Pharmaceuticals, Inc. | Reducing beta-catenin and IDO expression to potentiate immunotherapy |
| KR20210127917A (ko) * | 2018-12-12 | 2021-10-25 | 다이서나 파마수이티컬, 인크. | 트리루프를 함유하는 이중-가닥의 핵산 억제제 분자 |
| WO2023122316A2 (en) * | 2021-12-23 | 2023-06-29 | Aligos Therapeutics, Inc. | SPLICE SWITCH OLIGONUCLEOTIDE (SSO) MOLECULES FOR TARGETING β-CATENIN AND USES THEREOF |
| WO2023152351A1 (en) * | 2022-02-14 | 2023-08-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Treatment of liver cancers by disrupting the beta-catenin/tcf-4 binding site located upstream of meg3 in the dlk1/dio3 locus |
| JP2025536290A (ja) * | 2022-10-21 | 2025-11-05 | リカージョン ファーマシューティカルズ インコーポレイテッド | Ｗｎｔ経路腫瘍抑制因子に突然変異を有する癌の治療 |
| WO2025147555A1 (en) * | 2024-01-05 | 2025-07-10 | Recursion Pharmaceuticals, Inc. | Rec-4881 (tak-733) for use in treating or preventing colorectal cancer and related diseases |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002256398A2 (en) * | 2001-04-30 | 2002-11-11 | Targeted Genetics Corporation | Lipid-comprising drug delivery complexes and methods for their production |
| US8198427B1 (en) | 2002-11-14 | 2012-06-12 | Dharmacon, Inc. | SiRNA targeting catenin, beta-1 (CTNNB1) |
| WO2009029293A2 (en) | 2007-03-02 | 2009-03-05 | Mdrna, Inc. | Nucleic acid compounds for inhibiting myc gene expression and uses thereof |
| JP5976643B2 (ja) | 2010-07-06 | 2016-08-24 | ダイセルナ ファーマシューティカルズ， インコーポレイテッドＤｉｃｅｒｎａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 二本鎖ｒｎａによるベータ−カテニンの特異的阻害に対する方法と組成物 |
| US8518907B2 (en) * | 2010-08-02 | 2013-08-27 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA) |
| US20150073033A1 (en) * | 2011-10-31 | 2015-03-12 | Board Of Regents, The University Of Texas System | Biomarkers for cancer characterization and treatment |
| BR112014016870A2 (pt) * | 2012-01-09 | 2017-06-27 | Huesken Dieter | composições orgânicas para tratar doenças relacionadas com beta-catenina |
| US9562228B2 (en) * | 2012-09-14 | 2017-02-07 | Dicerna Pharmaceuticals, Inc. | Methods and compositions for the specific inhibition of MYC by double-stranded RNA |
| US10201556B2 (en) * | 2012-11-06 | 2019-02-12 | Interna Technologies B.V. | Combination for use in treating diseases or conditions associated with melanoma, or treating diseases or conditions associated with activated B-raf pathway |
| CA2904338C (en) | 2013-03-05 | 2022-07-05 | University Of Tennessee Research Foundation | Use of imidazole derivatives in combination with a braf inhibitor or mek inhibitor in the treatment of cancer |
| ES2733929T3 (es) * | 2013-07-12 | 2019-12-03 | Piramal Entpr Ltd | Una combinación farmacéutica para el tratamiento del melanoma |
| KR102186363B1 (ko) * | 2013-09-06 | 2020-12-04 | 삼성전자주식회사 | c-Met 저해제 및 베타-카테닌 저해제를 포함하는 병용 투여용 약학 조성물 |
| KR102192591B1 (ko) | 2013-09-09 | 2020-12-18 | 삼성전자주식회사 | c-Met 저해제 및 c-Myc 저해제를 포함하는 병용 투여용 약학 조성물 |
| US10111897B2 (en) * | 2013-10-03 | 2018-10-30 | Duke University | Compositions and methods for treating cancer with JAK2 activity |
| US9895312B2 (en) | 2014-04-08 | 2018-02-20 | Pablo E. Vivas-Mejia | Nanoliposomal c-MYC-siRNA inhibits in vivo tumor growth of cisplatin-resistant ovarian cancer |
| AU2017232496B2 (en) * | 2016-03-16 | 2022-11-24 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for the treatment of a beta-catenin-associated disease or disorder |
-
2017
- 2017-03-15 AU AU2017232496A patent/AU2017232496B2/en not_active Ceased
- 2017-03-15 CA CA3017963A patent/CA3017963A1/en active Pending
- 2017-03-15 JP JP2018568165A patent/JP6987084B2/ja not_active Expired - Fee Related
- 2017-03-15 WO PCT/US2017/022510 patent/WO2017160983A1/en not_active Ceased
- 2017-03-15 EP EP17767430.6A patent/EP3429598A4/en not_active Withdrawn
- 2017-03-15 US US16/084,852 patent/US10821112B2/en not_active Expired - Fee Related
-
2020
- 2020-09-29 US US17/036,369 patent/US11504374B2/en active Active
-
2021
- 2021-11-30 JP JP2021193759A patent/JP7321236B2/ja active Active
-
2022
- 2022-10-28 US US18/050,760 patent/US20230190753A1/en not_active Abandoned
-
2023
- 2023-02-17 AU AU2023200960A patent/AU2023200960A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019512543A5 (enExample) | ||
| Blagitko-Dorfs et al. | Combination treatment of acute myeloid leukemia cells with DNMT and HDAC inhibitors: predominant synergistic gene downregulation associated with gene body demethylation | |
| Liu et al. | Regulation of microRNAs by epigenetics and their interplay involved in cancer | |
| Costa et al. | Epigenetic reprogramming in cancer: From diagnosis to treatment | |
| Pastori et al. | Involvement of long noncoding RNAs in diseases affecting the central nervous system | |
| Schiffmann et al. | Epigenetic therapy approaches in non-small cell lung cancer: Update and perspectives | |
| BR112015022507A2 (pt) | ácidos ribonucleicos com nucleotídeos 4'-tio-modificados, composição compreendendo o mesmo e usos relacionados | |
| JP2015516989A5 (enExample) | ||
| MX2019002075A (es) | Composiciones que comprenden oligonucleotidos modificados reversiblemente, y sus usos. | |
| Blackledge et al. | CpG island chromatin is shaped by recruitment of ZF-CxxC proteins | |
| WO2016106406A3 (en) | Rna agents for gst-pi gene modulation | |
| HRP20201200T1 (hr) | OLIGONUKLEOTIDNI SPOJEVI ZA CILJANJE HUNTINGTIN mRNK | |
| JP2018529732A5 (enExample) | ||
| NZ730296A (en) | Modified double-stranded rna agents | |
| Mehdipour et al. | The next generation of DNMT inhibitors | |
| MX373926B (es) | Metodos para tratar cancer y estados no neoplasicos. | |
| JP2018513104A5 (enExample) | ||
| JP2015511821A5 (enExample) | ||
| RU2016141055A (ru) | Препараты арипипразола, имеющие повышенные скорости впрыска | |
| MX2010002278A (es) | Farmacos antivirales para el tratamiento de una infeccion por arenavirus. | |
| JP2013503202A5 (enExample) | ||
| Liu et al. | Cancer epigenetics and the potential of epigenetic drugs for treating solid tumors | |
| PH12020550436A1 (en) | NUCLEIC ACID MOLECULE FOR REDUCTION OF PAPD5 AND PAPD7 mRNA FOR TREATING HEPATITIS B INFECTION | |
| MX2019005101A (es) | Microarns modificados con 5-halouracilo y su uso en el tratamiento del cancer. | |
| Perera et al. | Peptide nucleic acids and their role in gene regulation and editing |